- Chord Therapeutics was launched by Omega Funds in October 2020 to develop new oral treatments for rare neuroinflammatory diseases
- Merck to accelerate development of Chord’s innovative pipeline for generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Focused expansion in neuroinflammatory diseases builds on Merck’s existing neurology portfolio in Multiple Sclerosis (MS)
Geneva, December 20, 2021: Chord Therapeutics (Chord), a clinical stage biopharmaceutical company developing drugs for rare neuroinflammatory diseases, today announces that it is being acquired by Merck, a leading science and technology company. The strategic acquisition enables Merck to expand its neurology pipeline to develop Chord’s lead drug candidate, CRD1 (cladribine), for the treatment of gMG and NMOSD
Chord Therapeutics was launched in October 2020 by leading healthcare venture capital firm Omega Funds, the sole investor in the Company’s USD 16 million Series A financing.